Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Kalaris Therapeutics, Inc. (KLRS) since 2020 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Kalaris Therapeutics, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1754068.
Total stock buying since 2020: $60,575,906.
Total stock sales since 2020: $43,139,607.
Total stock option exercises since 2020: $0.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 0 | $0 | 3,155 | $14,159 | 0 | $0 |
| 2024 | 0 | $0 | 235,981 | $168,764 | 0 | $0 |
| 2023 | 2,930,870 | $10,990,762 | 172,039 | $553,074 | 0 | $0 |
| 2022 | 10,000 | $67,544 | 1,314,769 | $10,029,825 | 0 | $0 |
| 2021 | 0 | $0 | 943,397 | $32,373,785 | 0 | $0 |
| 2020 | 2,912,800 | $49,517,600 | 0 | $0 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-03 | 0 | $0 | 907 | $8,134 | 0 | $0 |
| 2025-02 | 0 | $0 | 399 | $4,020 | 0 | $0 |
| 2025-01 | 0 | $0 | 1,849 | $2,005 | 0 | $0 |
| 2024-11 | 0 | $0 | 32,550 | $24,083 | 0 | $0 |
| 2024-10 | 0 | $0 | 18,657 | $14,607 | 0 | $0 |
| 2024-08 | 0 | $0 | 25,925 | $19,094 | 0 | $0 |
| 2024-07 | 0 | $0 | 3,111 | $2,238 | 0 | $0 |
| 2024-05 | 0 | $0 | 22,668 | $17,874 | 0 | $0 |
| 2024-04 | 0 | $0 | 17,216 | $12,963 | 0 | $0 |
| 2024-02 | 0 | $0 | 97,587 | $65,768 | 0 | $0 |
| 2024-01 | 0 | $0 | 18,267 | $12,137 | 0 | $0 |
| 2023-12 | 0 | $0 | 28,335 | $20,826 | 0 | $0 |
| 2023-11 | 0 | $0 | 9,964 | $16,512 | 0 | $0 |
| 2023-10 | 0 | $0 | 14,305 | $23,437 | 0 | $0 |
| 2023-08 | 0 | $0 | 27,585 | $70,042 | 0 | $0 |
| 2023-07 | 0 | $0 | 19,919 | $66,297 | 0 | $0 |
| 2023-06 | 2,930,870 | $10,990,762 | 5,045 | $28,453 | 0 | $0 |
| 2023-05 | 0 | $0 | 4,536 | $19,114 | 0 | $0 |
| 2023-04 | 0 | $0 | 11,788 | $43,568 | 0 | $0 |
| 2023-02 | 0 | $0 | 5,122 | $33,933 | 0 | $0 |
| 2023-01 | 0 | $0 | 45,440 | $230,892 | 0 | $0 |
| 2022-11 | 0 | $0 | 36,355 | $281,641 | 0 | $0 |
| 2022-10 | 0 | $0 | 618,846 | $5,232,321 | 0 | $0 |
| 2022-09 | 0 | $0 | 400,000 | $2,940,800 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-03-26 | Hagen Brett R (Chief Accounting Officer) | Sale | 907 | 8.97 | 8,134 |
| 2025-02-21 | Hagen Brett R (Chief Accounting Officer) | Sale | 96 | 10.08 | 967 |
| 2025-02-21 | Sinha Vikas (See Remarks) | Sale | 303 | 10.08 | 3,053 |
| 2025-01-23 | Sinha Vikas (See Remarks) | Sale | 129 | 9.70 | 1,250 |
| 2025-01-10 | Hagen Brett R (Chief Accounting Officer) | Sale | 332 | .44 | 146 |
| 2025-01-10 | Miller Edward (General Counsel) | Sale | 409 | .44 | 179 |
| 2025-01-10 | Sinha Vikas (See Remarks) | Sale | 979 | .44 | 430 |
| 2024-11-19 | Brainard Diana (Chief Executive Officer) | Sale | 8,706 | .55 | 4,779 |
| 2024-11-19 | Hagen Brett R (Chief Accounting Officer) | Sale | 554 | .55 | 304 |
| 2024-11-19 | Miller Edward (General Counsel) | Sale | 432 | .55 | 237 |
| 2024-11-19 | Sinha Vikas (See Remarks) | Sale | 3,186 | .55 | 1,749 |
| 2024-11-05 | Brainard Diana (Chief Executive Officer) | Sale | 10,609 | .86 | 9,176 |
| 2024-11-05 | Hagen Brett R (Chief Accounting Officer) | Sale | 1,655 | .86 | 1,431 |
| 2024-11-05 | Miller Edward (General Counsel) | Sale | 2,272 | .86 | 1,965 |
| 2024-11-05 | Sinha Vikas (See Remarks) | Sale | 5,136 | .86 | 4,442 |
| 2024-10-22 | Hagen Brett R (Chief Accounting Officer) | Sale | 486 | .77 | 373 |
| 2024-10-22 | Miller Edward (General Counsel) | Sale | 766 | .77 | 588 |
| 2024-10-22 | Sinha Vikas (See Remarks) | Sale | 1,882 | .77 | 1,445 |
| 2024-10-21 | Brainard Diana (Chief Executive Officer) | Sale | 9,752 | .78 | 7,596 |
| 2024-10-21 | Hagen Brett R (Chief Accounting Officer) | Sale | 479 | .78 | 373 |
| 2024-10-21 | Miller Edward (General Counsel) | Sale | 635 | .78 | 494 |
| 2024-10-21 | Sinha Vikas (See Remarks) | Sale | 1,546 | .78 | 1,204 |
| 2024-10-03 | Brainard Diana (Chief Executive Officer) | Sale | 1,493 | .81 | 1,216 |
| 2024-10-03 | Hagen Brett R (Chief Accounting Officer) | Sale | 301 | .81 | 245 |
| 2024-10-03 | Miller Edward (General Counsel) | Sale | 377 | .81 | 307 |
| 2024-10-03 | Sinha Vikas (See Remarks) | Sale | 940 | .81 | 766 |
| 2024-08-20 | Brainard Diana (Chief Executive Officer) | Sale | 5,390 | .74 | 3,993 |
| 2024-08-19 | Miller Edward (General Counsel) | Sale | 422 | .76 | 320 |
| 2024-08-05 | Brainard Diana (Chief Executive Officer) | Sale | 10,847 | .73 | 7,972 |
| 2024-08-05 | Hagen Brett R (Chief Accounting Officer) | Sale | 1,692 | .73 | 1,243 |
| 2024-08-05 | Miller Edward (General Counsel) | Sale | 2,323 | .73 | 1,707 |
| 2024-08-05 | Sinha Vikas (See Remarks) | Sale | 5,251 | .73 | 3,859 |
| 2024-07-02 | Brainard Diana (Chief Executive Officer) | Sale | 1,489 | .72 | 1,072 |
| 2024-07-02 | Hagen Brett R (Chief Accounting Officer) | Sale | 304 | .72 | 218 |
| 2024-07-02 | Miller Edward (General Counsel) | Sale | 379 | .72 | 272 |
| 2024-07-02 | Sinha Vikas (See Remarks) | Sale | 939 | .72 | 676 |
| 2024-05-17 | Miller Edward (General Counsel) | Sale | 420 | .75 | 314 |
| 2024-05-17 | Sinha Vikas (See Remarks) | Sale | 3,143 | .75 | 2,354 |
| 2024-05-03 | Brainard Diana (Chief Executive Officer) | Sale | 10,240 | .80 | 8,151 |
| 2024-05-03 | Hagen Brett R (Chief Accounting Officer) | Sale | 1,597 | .80 | 1,271 |
| 2024-05-03 | Miller Edward (General Counsel) | Sale | 2,311 | .80 | 1,839 |
| 2024-05-03 | Sinha Vikas (See Remarks) | Sale | 4,957 | .80 | 3,945 |
| 2024-04-22 | Hagen Brett R (Chief Accounting Officer) | Sale | 480 | .75 | 360 |
| 2024-04-22 | Miller Edward (General Counsel) | Sale | 757 | .75 | 567 |
| 2024-04-22 | Sinha Vikas (See Remarks) | Sale | 1,857 | .75 | 1,392 |
| 2024-04-19 | Brainard Diana (Chief Executive Officer) | Sale | 9,601 | .75 | 7,210 |
| 2024-04-19 | Hagen Brett R (Chief Accounting Officer) | Sale | 473 | .75 | 355 |
| 2024-04-19 | Miller Edward (General Counsel) | Sale | 626 | .75 | 470 |
| 2024-04-19 | Sinha Vikas (See Remarks) | Sale | 1,521 | .75 | 1,142 |
| 2024-04-02 | Brainard Diana (Chief Executive Officer) | Sale | 1,533 | .77 | 1,183 |
| 2024-04-02 | Miller Edward (General Counsel) | Sale | 368 | .77 | 284 |
| 2024-02-21 | Brainard Diana (Chief Executive Officer) | Sale | 5,155 | .71 | 3,649 |
| 2024-02-20 | Brainard Diana (Chief Executive Officer) | Sale | 3,097 | .69 | 2,152 |
| 2024-02-20 | Hagen Brett R (Chief Accounting Officer) | Sale | 494 | .69 | 343 |
| 2024-02-20 | Miller Edward (General Counsel) | Sale | 385 | .69 | 267 |
| 2024-02-20 | Sinha Vikas (See Remarks) | Sale | 2,893 | .69 | 2,010 |
| 2024-02-08 | Hagen Brett R (Chief Accounting Officer) | Sale | 11,150 | .67 | 7,492 |
| 2024-02-05 | Brainard Diana (Chief Executive Officer) | Sale | 41,421 | .67 | 27,752 |
| 2024-02-05 | Hagen Brett R (Chief Accounting Officer) | Sale | 5,792 | .67 | 3,880 |
| 2024-02-05 | Miller Edward (General Counsel) | Sale | 8,869 | .67 | 5,942 |
| 2024-02-05 | Sinha Vikas (See Remarks) | Sale | 18,331 | .67 | 12,281 |
| 2024-01-23 | Brainard Diana (Chief Executive Officer) | Sale | 9,500 | .67 | 6,365 |
| 2024-01-23 | Hagen Brett R (Chief Accounting Officer) | Sale | 901 | .67 | 604 |
| 2024-01-23 | Miller Edward (General Counsel) | Sale | 1,302 | .67 | 873 |
| 2024-01-23 | Sinha Vikas (See Remarks) | Sale | 3,205 | .67 | 2,150 |
| 2024-01-04 | Brainard Diana (Chief Executive Officer) | Sale | 1,664 | .64 | 1,063 |
| 2024-01-04 | Hagen Brett R (Chief Accounting Officer) | Sale | 310 | .64 | 198 |
| 2024-01-04 | Miller Edward (General Counsel) | Sale | 424 | .64 | 270 |
| 2024-01-04 | Sinha Vikas (See Remarks) | Sale | 961 | .64 | 614 |
| 2023-12-27 | Hagen Brett R (Chief Accounting Officer) | Sale | 28,335 | .73 | 20,826 |
| 2023-11-20 | Brainard Diana (Chief Executive Officer) | Sale | 4,382 | 1.69 | 7,409 |
| 2023-11-17 | Brainard Diana (Chief Executive Officer) | Sale | 2,689 | 1.63 | 4,385 |
| 2023-11-17 | Hagen Brett R (Chief Accounting Officer) | Sale | 403 | 1.63 | 657 |
| 2023-11-17 | Sinha Vikas (See Remarks) | Sale | 2,490 | 1.63 | 4,061 |
| 2023-10-20 | Hagen Brett R (Chief Accounting Officer) | Sale | 357 | 1.54 | 550 |
| 2023-10-20 | Sinha Vikas (See Remarks) | Sale | 1,475 | 1.54 | 2,272 |
| 2023-10-19 | Brainard Diana (Chief Executive Officer) | Sale | 8,581 | 1.58 | 13,557 |
| 2023-10-19 | Hagen Brett R (Chief Accounting Officer) | Sale | 358 | 1.58 | 565 |
| 2023-10-19 | Sinha Vikas (See Remarks) | Sale | 1,232 | 1.58 | 1,946 |
| 2023-10-03 | Brainard Diana (Chief Executive Officer) | Sale | 1,325 | 1.98 | 2,618 |
| 2023-10-03 | Hagen Brett R (Chief Accounting Officer) | Sale | 222 | 1.98 | 438 |
| 2023-10-03 | Sinha Vikas (See Remarks) | Sale | 755 | 1.98 | 1,491 |
| 2023-08-18 | Brainard Diana (Chief Executive Officer) | Sale | 4,055 | 2.79 | 11,313 |
| 2023-08-17 | Brainard Diana (Chief Executive Officer) | Sale | 11,361 | 2.50 | 28,357 |
| 2023-08-17 | Hagen Brett R (Chief Accounting Officer) | Sale | 1,653 | 2.50 | 4,125 |
| 2023-08-17 | Sinha Vikas (See Remarks) | Sale | 10,516 | 2.50 | 26,247 |
| 2023-07-20 | Hagen Brett R (Chief Accounting Officer) | Sale | 342 | 3.35 | 1,144 |
| 2023-07-20 | Sinha Vikas (See Remarks) | Sale | 1,437 | 3.35 | 4,809 |
| 2023-07-19 | Brainard Diana (Chief Executive Officer) | Sale | 8,342 | 3.56 | 29,714 |
| 2023-07-19 | Hagen Brett R (Chief Accounting Officer) | Sale | 342 | 3.56 | 1,218 |
| 2023-07-19 | Sinha Vikas (See Remarks) | Sale | 1,198 | 3.56 | 4,267 |
| 2023-07-05 | Brainard Diana (Chief Executive Officer) | Sale | 5,275 | 3.04 | 16,062 |
| 2023-07-05 | Sinha Vikas (See Remarks) | Sale | 2,983 | 3.04 | 9,083 |
| 2023-06-27 | Gilead Sciences, Inc. (10% Owner) | Buy | 2,930,870 | 3.75 | 10,990,762 |
| 2023-06-09 | Hagen Brett R (Chief Accounting Officer) | Sale | 5,045 | 5.64 | 28,453 |
| 2023-05-18 | Brainard Diana (Chief Executive Officer) | Sale | 4,536 | 4.21 | 19,114 |
| 2023-04-20 | Hagen Brett R (Chief Accounting Officer) | Sale | 349 | 3.63 | 1,265 |
| 2023-04-20 | Sinha Vikas (See Remarks) | Sale | 1,466 | 3.63 | 5,315 |
| 2023-04-19 | Brainard Diana (Chief Executive Officer) | Sale | 8,408 | 3.71 | 31,185 |
| 2023-04-19 | Hagen Brett R (Chief Accounting Officer) | Sale | 348 | 3.71 | 1,290 |
| 2023-04-19 | Sinha Vikas (See Remarks) | Sale | 1,217 | 3.71 | 4,513 |
| 2023-02-21 | Brainard Diana (Chief Executive Officer) | Sale | 5,122 | 6.62 | 33,933 |
| 2023-01-20 | Hagen Brett R (Chief Accounting Officer) | Sale | 338 | 5.14 | 1,738 |
| 2023-01-20 | Miller Edward (General Counsel) | Sale | 541 | 5.14 | 2,782 |
| 2023-01-20 | Sinha Vikas (See Remarks) | Sale | 1,426 | 5.14 | 7,335 |
| 2023-01-19 | Brainard Diana (Chief Executive Officer) | Sale | 34,435 | 5.08 | 174,860 |
| 2023-01-19 | Hagen Brett R (Chief Accounting Officer) | Sale | 1,557 | 5.08 | 7,906 |
| 2023-01-19 | Miller Edward (General Counsel) | Sale | 2,032 | 5.08 | 10,318 |
| 2023-01-19 | Sinha Vikas (See Remarks) | Sale | 5,111 | 5.08 | 25,953 |
| 2022-11-18 | Brainard Diana (Chief Executive Officer) | Sale | 4,515 | 7.27 | 32,810 |
| 2022-11-16 | Van Beek Jeroen B (Chief Commercial Officer) | Sale | 16,074 | 7.50 | 120,522 |
| 2022-11-14 | Miller Edward (General Counsel) | Sale | 2,358 | 8.91 | 21,019 |
| 2022-11-10 | Van Beek Jeroen B (Chief Commercial Officer) | Sale | 13,109 | 8.00 | 104,898 |
| 2022-11-08 | Van Beek Jeroen B (Chief Commercial Officer) | Sale | 299 | 8.00 | 2,392 |
| 2022-10-24 | Hagen Brett R (Chief Accounting Officer) | Sale | 2,000 | 8.13 | 16,270 |
| 2022-10-21 | Hagen Brett R (Chief Accounting Officer) | Sale | 11,334 | 8.45 | 95,794 |
| 2022-10-20 | Atillasoy Ercem (See Remarks) | Sale | 1,527 | 8.48 | 12,955 |
| 2022-10-19 | Atillasoy Ercem (See Remarks) | Sale | 568 | 9.36 | 5,317 |
| 2022-10-19 | Van Beek Jeroen B (Chief Commercial Officer) | Sale | 1,070 | 9.36 | 10,016 |
| 2022-10-19 | Hagen Brett R (Chief Accounting Officer) | Sale | 345 | 9.36 | 3,229 |
| 2022-10-19 | Miller Edward (General Counsel) | Sale | 553 | 9.36 | 5,176 |
| 2022-10-19 | Hallal David (Director) | Sale | 600,000 | 8.45 | 5,070,000 |
| 2022-10-19 | Sinha Vikas (See Remarks) | Sale | 1,449 | 9.36 | 13,564 |
| 2022-09-29 | Hallal David (Director) | Sale | 400,000 | 7.35 | 2,940,800 |
| 2022-08-16 | Van Beek Jeroen B (Chief Commercial Officer) | Sale | 15,590 | 8.30 | 129,474 |
| 2022-07-21 | Atillasoy Ercem (See Remarks) | Sale | 1,533 | 5.38 | 8,244 |
| 2022-07-21 | Hallal David (Director) | Sale | 4,227 | 5.33 | 22,529 |
| 2022-07-20 | Atillasoy Ercem (See Remarks) | Sale | 563 | 5.21 | 2,936 |
| 2022-07-20 | Van Beek Jeroen B (Chief Commercial Officer) | Sale | 1,058 | 5.21 | 5,517 |
| 2022-07-20 | Sinha Vikas (See Remarks) | Sale | 1,432 | 5.21 | 7,467 |
| 2022-06-03 | Van Beek Jeroen B (Chief Commercial Officer) | Sale | 515 | 3.63 | 1,870 |
| 2022-06-03 | Hallal David (Director) | Sale | 65,725 | 3.67 | 241,079 |
| 2022-05-18 | Brainard Diana (Chief Executive Officer) | Sale | 29,135 | 4.33 | 126,271 |
| 2022-05-17 | Van Beek Jeroen B (Chief Commercial Officer) | Sale | 15,262 | 4.40 | 67,168 |
| 2022-04-26 | Bornstein Jeffrey S (Director) | Buy | 5,000 | 4.64 | 23,195 |
| 2022-04-21 | Atillasoy Ercem (See Remarks) | Sale | 1,587 | 5.86 | 9,301 |
| 2022-04-21 | Hallal David (Director) | Sale | 4,227 | 5.87 | 24,812 |
| 2022-04-20 | Atillasoy Ercem (See Remarks) | Sale | 453 | 6.68 | 3,027 |
| 2022-04-20 | Van Beek Jeroen B (Chief Commercial Officer) | Sale | 852 | 6.68 | 5,694 |
| 2022-04-20 | Hagen Brett R (Chief Accounting Officer) | Sale | 276 | 6.68 | 1,844 |
| 2022-04-20 | Sinha Vikas (See Remarks) | Sale | 1,162 | 6.68 | 7,766 |
| 2022-03-11 | Hallal David (Director) | Sale | 25,244 | 7.37 | 186,073 |
| 2022-03-10 | Hallal David (Director) | Sale | 40,481 | 7.55 | 305,793 |
| 2022-03-02 | Van Beek Jeroen B (Chief Commercial Officer) | Sale | 516 | 9.01 | 4,651 |
| 2022-02-16 | Van Beek Jeroen B (Chief Commercial Officer) | Sale | 15,322 | 8.32 | 127,525 |
| 2022-02-10 | Bornstein Jeffrey S (Director) | Buy | 5,000 | 8.87 | 44,349 |
| 2022-01-25 | Atillasoy Ercem (See Remarks) | Sale | 4,639 | 8.24 | 38,248 |
| 2022-01-24 | Hallal David (Director) | Sale | 17,100 | 8.01 | 136,885 |
| 2022-01-20 | Van Beek Jeroen B (Chief Commercial Officer) | Sale | 4,656 | 8.75 | 40,753 |
| 2022-01-20 | Hagen Brett R (Chief Accounting Officer) | Sale | 1,563 | 8.75 | 13,680 |
| 2022-01-20 | Sinha Vikas (See Remarks) | Sale | 6,450 | 8.75 | 56,456 |
| 2021-12-02 | Van Beek Jeroen B (Chief Commercial Officer) | Sale | 514 | 17.06 | 8,770 |
| 2021-11-16 | Leen Ann M. (Chief Scientific Officer) | Sale | 100 | 21.76 | 2,176 |
| 2021-11-16 | Van Beek Jeroen B (Chief Commercial Officer) | Sale | 15,203 | 21.13 | 321,269 |
| 2021-11-15 | Leen Ann M. (Chief Scientific Officer) | Sale | 6,122 | 21.92 | 134,169 |
| 2021-11-12 | Leen Ann M. (Chief Scientific Officer) | Sale | 14,766 | 22.72 | 335,498 |
| 2021-11-10 | Jovan-embiricos Morana (Director) | Sale | 800 | 24.77 | 19,812 |
| 2021-11-09 | Jovan-embiricos Morana (Director) | Sale | 3,815 | 24.79 | 94,566 |
| 2021-11-05 | Jovan-embiricos Morana (Director) | Sale | 8,381 | 24.80 | 207,890 |
| 2021-10-27 | Jovan-embiricos Morana (Director) | Sale | 2,200 | 24.78 | 54,511 |
| 2021-10-25 | Jovan-embiricos Morana (Director) | Sale | 7,769 | 24.82 | 192,811 |
| 2021-10-22 | Jovan-embiricos Morana (Director) | Sale | 5,723 | 24.77 | 141,758 |
| 2021-10-21 | Atillasoy Ercem (See Remarks) | Sale | 1,514 | 24.23 | 36,690 |
| 2021-10-21 | Jovan-embiricos Morana (Director) | Sale | 100 | 24.75 | 2,475 |
| 2021-10-04 | Melian Agustin (Chief Medical Officer) | Sale | 18,689 | 24.74 | 462,291 |
| 2021-10-01 | Van Beek Jeroen B (Chief Commercial Officer) | Sale | 3,413 | 25.07 | 85,574 |
| 2021-09-30 | Van Beek Jeroen B (Chief Commercial Officer) | Sale | 12,171 | 25.17 | 306,295 |
| 2021-09-29 | Van Beek Jeroen B (Chief Commercial Officer) | Sale | 1,000 | 25.04 | 25,037 |
| 2021-09-28 | Melian Agustin (Chief Medical Officer) | Sale | 3,750 | 24.11 | 90,431 |
| 2021-09-17 | Melian Agustin (Chief Medical Officer) | Sale | 2,950 | 24.01 | 70,841 |
| 2021-09-17 | Van Beek Jeroen B (Chief Commercial Officer) | Sale | 5,916 | 25.08 | 148,361 |
| 2021-09-15 | Melian Agustin (Chief Medical Officer) | Sale | 800 | 24.03 | 19,224 |
| 2021-09-02 | Van Beek Jeroen B (Chief Commercial Officer) | Sale | 513 | 19.86 | 10,188 |
| 2021-08-17 | Van Beek Jeroen B (Chief Commercial Officer) | Sale | 15,205 | 17.82 | 270,953 |
| 2021-07-02 | Melian Agustin (Chief Medical Officer) | Sale | 18,586 | 19.99 | 371,534 |
| 2021-06-03 | Van Beek Jeroen B (Chief Commercial Officer) | Sale | 508 | 22.87 | 11,617 |
| 2021-05-18 | Van Beek Jeroen B (Chief Commercial Officer) | Sale | 15,201 | 22.80 | 346,582 |
| 2021-04-05 | Melian Agustin (Chief Medical Officer) | Sale | 18,212 | 23.89 | 435,084 |
| 2021-03-22 | Melian Agustin (Chief Medical Officer) | Sale | 3,750 | 25.97 | 97,395 |
| 2021-03-16 | Leen Ann M. (Chief Scientific Officer) | Sale | 3,025 | 30.00 | 90,750 |
| 2021-03-11 | Wilson John Robert (Director) | Sale | 16,662 | 31.25 | 520,687 |
| 2021-03-10 | Wilson John Robert (Director) | Sale | 72,745 | 31.61 | 2,299,542 |
| 2021-03-09 | Wilson John Robert (Director) | Sale | 110,595 | 31.50 | 3,483,300 |
| 2021-03-05 | Brenner Malcolm (Director) | Sale | 48,091 | 32.31 | 1,553,916 |
| 2021-03-04 | Brenner Malcolm (Director) | Sale | 49,598 | 36.03 | 1,786,966 |
| 2021-03-03 | Brenner Malcolm (Director) | Sale | 17,915 | 37.72 | 675,807 |
| 2021-03-03 | Vera Juan (Director) | Sale | 15,988 | 37.95 | 606,808 |
| 2021-03-02 | Brenner Malcolm (Director) | Sale | 12,658 | 38.25 | 484,206 |
| 2021-03-02 | Vera Juan (Director) | Sale | 14,994 | 38.23 | 573,145 |
| 2021-03-02 | Van Beek Jeroen B (Chief Commercial Officer) | Sale | 512 | 37.93 | 19,420 |
| 2021-03-01 | Brenner Malcolm (Director) | Sale | 21,694 | 38.70 | 839,449 |
| 2021-03-01 | Leen Ann M. (Chief Scientific Officer) | Sale | 9,518 | 38.82 | 369,469 |
| 2021-03-01 | Vera Juan (Director) | Sale | 32,854 | 38.85 | 1,276,246 |
| 2021-03-01 | Van Beek Jeroen B (Chief Commercial Officer) | Sale | 5,932 | 38.91 | 230,837 |
| 2021-03-01 | Miller Edward (General Counsel) | Sale | 6,000 | 38.86 | 233,147 |
| 2021-02-23 | Brenner Malcolm (Director) | Sale | 8,489 | 39.95 | 339,144 |
| 2021-02-23 | Leen Ann M. (Chief Scientific Officer) | Sale | 4,199 | 39.66 | 166,528 |
| 2021-02-23 | Vera Juan (Director) | Sale | 8,850 | 39.63 | 350,752 |
| 2021-02-23 | Van Beek Jeroen B (Chief Commercial Officer) | Sale | 2,118 | 39.75 | 84,194 |
| 2021-02-22 | Brenner Malcolm (Director) | Sale | 11,423 | 42.59 | 486,459 |
| 2021-02-22 | Leen Ann M. (Chief Scientific Officer) | Sale | 5,706 | 42.19 | 240,730 |
| 2021-02-22 | Vera Juan (Director) | Sale | 14,321 | 42.59 | 609,988 |
| 2021-02-22 | Van Beek Jeroen B (Chief Commercial Officer) | Sale | 2,800 | 42.17 | 118,084 |
| 2021-02-22 | Hagen Brett R (Chief Accounting Officer) | Sale | 800 | 43.14 | 34,508 |
| 2021-02-19 | Brenner Malcolm (Director) | Sale | 11,990 | 41.78 | 500,930 |
| 2021-02-19 | Leen Ann M. (Chief Scientific Officer) | Sale | 7,541 | 41.75 | 314,866 |
| 2021-02-19 | Vera Juan (Director) | Sale | 13,233 | 41.79 | 553,007 |
| 2021-02-19 | Van Beek Jeroen B (Chief Commercial Officer) | Sale | 4,165 | 41.71 | 173,717 |
| 2021-02-18 | Brenner Malcolm (Director) | Sale | 6,757 | 40.50 | 273,678 |
| 2021-02-18 | Leen Ann M. (Chief Scientific Officer) | Sale | 2,700 | 40.38 | 109,026 |
| 2021-02-18 | Vera Juan (Director) | Sale | 8,942 | 40.47 | 361,891 |
| 2021-02-18 | Van Beek Jeroen B (Chief Commercial Officer) | Sale | 2,085 | 40.59 | 84,632 |
| 2021-02-18 | Hagen Brett R (Chief Accounting Officer) | Sale | 741 | 39.87 | 29,546 |
| 2021-02-18 | Bornstein Jeffrey S (Director) | Sale | 20,583 | 40.83 | 840,445 |
| 2021-02-17 | Brenner Malcolm (Director) | Sale | 5,165 | 40.48 | 209,063 |
| 2021-02-17 | Leen Ann M. (Chief Scientific Officer) | Sale | 2,286 | 39.92 | 91,254 |
| 2021-02-17 | Vera Juan (Director) | Sale | 7,460 | 39.99 | 298,325 |
| 2021-02-17 | Van Beek Jeroen B (Chief Commercial Officer) | Sale | 17,496 | 39.94 | 695,050 |
| 2021-02-17 | Hagen Brett R (Chief Accounting Officer) | Sale | 2,320 | 40.32 | 93,537 |
| 2021-02-16 | Brenner Malcolm (Director) | Sale | 6,220 | 42.38 | 263,584 |
| 2021-02-16 | Leen Ann M. (Chief Scientific Officer) | Sale | 3,050 | 42.30 | 129,024 |
| 2021-02-16 | Vera Juan (Director) | Sale | 10,400 | 42.16 | 438,474 |
| 2021-02-16 | Van Beek Jeroen B (Chief Commercial Officer) | Sale | 3,100 | 42.14 | 130,643 |
| 2021-02-16 | Hagen Brett R (Chief Accounting Officer) | Sale | 3,050 | 42.25 | 128,856 |
| 2021-02-02 | Melian Agustin (Chief Medical Officer) | Sale | 54,849 | 41.19 | 2,259,230 |
| 2021-02-02 | Van Beek Jeroen B (Chief Commercial Officer) | Sale | 48,910 | 41.19 | 2,014,602 |
| 2020-08-03 | Atillasoy Ercem (See Remarks) | Buy | 3,500 | 17.00 | 59,500 |
| 2020-08-03 | Brainard Diana (Director) | Buy | 6,300 | 17.00 | 107,100 |
| 2020-08-03 | Van Beek Jeroen B (Chief Commercial Officer) | Buy | 3,000 | 17.00 | 51,000 |
| 2020-08-03 | Jovan-embiricos Morana (Director) | Buy | 2,900,000 | 17.00 | 49,300,000 |
Insider trading activities including stock purchases, stock sales, and option exercises of KLRS listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Kalaris Therapeutics, Inc. (symbol KLRS, CIK number 1754068) see the Securities and Exchange Commission (SEC) website.